---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-005679"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:34:17.238367+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vistagen gets 180-day Nasdaq extension to Sept 5, 2023 to regain $1 bid price compliance

## Summary
- Company failed to meet $1.00 minimum bid price by March 6, 2023 deadline.
- Nasdaq granted extension until September 5, 2023 to cure deficiency.
- If not compliant by Sept 5, Nasdaq will initiate delisting; company may appeal.
- No effect on current listing; trading continues on Nasdaq Capital Market.
- Previously disclosed in September 2022 that bid price had been below $1 for 30 consecutive days.

## SEC filing metadata
- accession: 0001437749-23-005679
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774923005679/0001437749-23-005679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774923005679/vtgn20230307_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-005679
- JSON: https://secwatch.observer/filing/0001437749-23-005679.json
- Plain text: https://secwatch.observer/filing/0001437749-23-005679.txt

## Key facts
- Listing & Compliance Notices
  Vistagen Therapeutics, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 5, 2023 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement ”). The Extension Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market. The Company's listing on the Nasdaq Capital Market remains fully effective. As previously disclosed in th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923005679/0001437749-23-005679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.